LBRX
NASDAQLB Pharmaceuticals Inc
Price$31.42-0.29 (-0.93%)
02:15 PM07:45 PM
News · 26 weeks52-69%
2026-01-182026-07-12
Mix2690d
- SEC Filings10(38%)
- Insider7(27%)
- Other5(19%)
- Analyst2(8%)
- Leadership2(8%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by LB Pharmaceuticals IncSCHEDULE 13G - LB PHARMACEUTICALS INC (0001691082) (Subject)
- PRLB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), today announced that it has granted to Christopher Zergebel, the new Senior Vice President, Clinical Operations of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on July 10, 2026, pursuant to the "inducement grant" exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Mr. Zergebel entering into employment with LB Pharmaceuticals. Mr. Zergebel received an option to purchase 75,000 shares of LB Pharmaceuticals’ co
- ANALYSTWolfe Research initiated coverage on LB Pharmaceuticals with a new price targetWolfe Research initiated coverage of LB Pharmaceuticals with a rating of Outperform and set a new price target of $45.00
- PRLB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical OperationsNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations. Mr. Zergebel, a seasoned biotechnology executive with more than 25 years of global development operations experience, brings deep expertise in growing and leading cross-functional teams including clinical operations, data management, and project and portfolio management. "We ar
- SECSEC Form 424B3 filed by LB Pharmaceuticals Inc424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form 8-K filed by LB Pharmaceuticals Inc8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form 144 filed by LB Pharmaceuticals Inc144 - LB PHARMACEUTICALS INC (0001691082) (Subject)
- SECSEC Form 424B3 filed by LB Pharmaceuticals Inc424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form 8-K filed by LB Pharmaceuticals Inc8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
- INSIDERSEC Form 4 filed by Director Ruffolo Robert R4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Nussbaum Ran4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Luse Rebecca4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Lenz Robert A.4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Hemrajani Rekha4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Kane William P Jr4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Garland J. Scott4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- PRLB Pharmaceuticals to Participate in Upcoming June Investor EventsNEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced that members of its executive team, will present and participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 2:35 p.m. ET H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference Date: Tuesday, June 16, 2026 Time: Presentation available on the LB Pharmaceuticals w
- SECAmendment: SEC Form SCHEDULE 13G/A filed by LB Pharmaceuticals IncSCHEDULE 13G/A - LB PHARMACEUTICALS INC (0001691082) (Subject)
- SECSEC Form 424B3 filed by LB Pharmaceuticals Inc424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form 10-Q filed by LB Pharmaceuticals Inc10-Q - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECLB Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
- PRLB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateInitiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1 trial of LB-102 in schizophrenia in The Journal of the American Medical Association (JAMA) Psychiatry Expanded pipeline following $100 million private placement with plans to initiate a Phase 2 trial of LB-102 in adjunctive treatment of major depressive disorder (MDD) in early 2027 Cash, cash equivalents, and marketable securities of $365.6 million as of March 31, 2026 expected to fund operations into Q2 2029, through multiple clinical milestones NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -
- ANALYSTH.C. Wainwright initiated coverage on LB Pharmaceuticals with a new price targetH.C. Wainwright initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $45.00
- SECSEC Form DEFA14A filed by LB Pharmaceuticals IncDEFA14A - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form DEF 14A filed by LB Pharmaceuticals IncDEF 14A - LB PHARMACEUTICALS INC (0001691082) (Filer)
LBRX FAQ
6 questionsWhere does LBRX stock trade?
LB Pharmaceuticals Inc (LBRX) is listed on NASDAQ.What sector and industry is LBRX in?
LB Pharmaceuticals Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did LB Pharmaceuticals Inc go public?
LB Pharmaceuticals Inc (LBRX) completed its IPO in 2025.What are analysts saying about LBRX?
LB Pharmaceuticals Inc has had 7 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform with a $4500.00 price target on 2026-07-07. Recent price targets range from $2700.00 to $4500.00.What companies are similar to LBRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LBRX side-by-side with any of them on Quantisnow.How can I track LBRX on Quantisnow?
Quantisnow aggregates LB Pharmaceuticals Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LBRX to receive live email and push alerts on every new disclosure.